Market Size and Growth
As per the CRISPR and Cas Genes Market size analysis conducted by the CMI Team, the global CRISPR and Cas genes market is expected to record a CAGR of 17.14% from 2025 to 2034. In 2025, the market size is projected to reach a valuation of USD 5.6 Billion. By 2034, the valuation is anticipated to reach USD 23.4 Billion.
Overview
As per the industry experts at CMI, Major companies within the market of CRISPR and Cas genes, which include Thermo Fisher Scientific, Illumina, Agilent Technologies, and Synthego, are increasing innovation as well as production within gene editing technologies. These companies are focusing on AI-driven design processes, automated systems, and synthetic RNA to improve accuracy and scalability.
Other focus areas include the development of therapeutics, functional genomics and agricultural biotechnology. Strategic partnerships with academic and clinical institutions are expanding scope and regulatory readiness. Environmental, social, and governance (ESG) as well as FDA and ISO standards are simultaneously gaining priority. These initiatives are furthering leadership in the industry’s rapidly expanding CRISPR segment.
Key Trends & Drivers
Rising incidence of genetic and rare inherited disorders: The implementation of CRISPR Technology is advancing because of its potential to treat inherited and rare genetic disorders such as sickle cell anemia and beta-thalassemia. These disorders are the focus of clinical trials for gene therapy due to their limited treatment options. Vertex and CRISPR Therapeutics were granted FDA approval for Casgevy, the very first therapy created using CRISPR technology.
The therapy not only serves as a breakthrough in the treatment of sickle cell disease but also accelerates investment and partnerships intended to develop treatments for rare diseases. By 2025, the global rare disease therapeutics market is projected to exceed USD 240 billion, a significant portion of which can be targeted using CRISPR Technology. This development has the potential to increase the scope of CRISPR used in monogenic disorders. With more therapies approved, demand for these products will continue to rise.
Soaring need for better crop traits: There is also a soaring need in agriculture for improved crop attributes, and gene editing is the answer. The ability to produce high-yield, disease resistant, and climate resilient crops is now possible without extraneous DNA through CRISPR technology which allows these crops to sidestep GMO classification in certain regions. This may facilitate regulatory approval and market acceptance.
In May 2024, the Indian Council of Agricultural Research (ICAR) published a report on the field testing of rice lines created using CRISPR technology which had enhanced drought resistance and higher bioavailable iron. This initiative is expected to help millions while also decreasing dependency on fertilizers. The global market for gene-edited crops is anticipated to surpass USD 20 billion by 2025. Countries in the Asia-Pacific region as well as those in Latin America are actively funding these kinds of projects. Responding to the food and climate crisis, CRISPR’s unique technologies offer unprecedented speed and precision.
Incorporation of AI technologies for designing guide RNAs and predicting off-target effects: The application of AI in CRISPR is enabling more sophisticated guide RNA design, lowering the probability of off-target effects, and speeding up drug discovery processes. The incorporation of a modeling tool improves precision alongside safety for certain gene-editing techniques. In March 2025, Synthego released an AI-powered gRNA design platform that improves precision targeting by over forty percent while improving turnaround time for completion of projects.
This also corresponds with the rising need for tailored modifications in Biotech research and development. The AI in Genomics market will grow to USD 7.2 billion by 2025, a considerable share attributed to the usage of CRISPR technology. The use of cloud algorithms in the laboratory is now commonplace. As AI tools develop, CRISPR accuracy will expand even further.
Report Scope
| Feature of the Report | Details |
| Market Size in 2025 | USD 5.6 Billion |
| Projected Market Size in 2034 | USD 23.4 Billion |
| Market Size in 2024 | USD 4.9 Billion |
| CAGR Growth Rate | 17.14% CAGR |
| Base Year | 2024 |
| Forecast Period | 2025-2034 |
| Key Segment | By Technology Type, Delivery Method, Application Area, Tool Type, Crop Type, Disease Type and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
| Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
SWOT Analysis
- Strengths: The CRISPR technology is useful for therapeutics, advancing agriculture, and gene editing with efficiency and precision. Companies in the biotech industry, including Thermo Fisher, Illumina, and Synthego, endorse and sponsor its development. In addition, the new tools derived from AI technologies are improving the accuracy and efficiency of CRISPR. A strong partnership between the industry and academia has been beneficial for innovation.
- Weaknesses: CRISPR’s implementation in clinics is greatly limited due to safety, off-target effect, and efficacy concerns. These smaller laboratories may face challenges in adopting the technology due to high cost, complicated licensing, and heavy regulation. Public acceptance issues take longer to resolve due to ethical considerations tied to embryo editing. The absence of harmonization creates region-specific divergent pathways leading to regulatory approval which is unfortunate. Patent disputes could block adoption and slow down innovative advancements.
- Opportunities: Rare diseases, crop improvement, and even the creation of rapid diagnostic tests can all benefit from CRISPR technology. There are unrealized commercial prospects with synthetic biology, artificial intelligence, and advanced delivery systems. Interest in the Asia-Pacific region is surging with a focus on agriculture and public health. The rise of personalized medicine is expanding the market for CRISPR-based therapies. There is still room for expansion with government investments in foreign markets supporting global collaborations.
- Threat: Harsh policies and public skepticism can stall market adoption. Other base editing and RNA interference also pose threats. There may also be geopolitical risks to global supply chains. Limitations on clinical trials due to safety checks may hinder progress. The lack of defined reimbursement frameworks may limit the therapy’s accessibility.
List of the prominent players in the CRISPR and Cas Genes Market:
- Thermo Fisher Scientific
- Illumina
- Agilent Technologies
- Synthego
- Danaher
- Origene Technologies
- GenScript
- Lonza
- Revvity Inc.
- Merck KGaA
- Others
The CRISPR and Cas Genes Market is segmented as follows:
By Technology Type
- CRISPR/Cas9
- CRISPR/Cas13
- CRISPR/Cas14
- Others
By Delivery Method
- Ex vivo
- In vivo
- Physical Methods
- Others
By Application Area
- Functional Genomics
- Oncology
- Infectious Diseases
- Others
By Tool Type
- Guide RNA
- CRISPR Plasmids
- Cas Nucleases
- Custom CRISPR Libraries
- Vectors & Cloning Kits
By Crop Type
- Cereals & Grains
- Fruits & Vegetables
- Oilseeds & Pulses
- Industrial Crops
By Disease Type
- Cancer
- Blood Disorders
- Ophthalmic Diseases
- Infectious Diseases
- Others
Regional Coverage:
North America
- U.S.
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- France
- U.K.
- Russia
- Italy
- Spain
- Netherlands
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Taiwan
- Rest of Asia Pacific
The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America